key: cord-0703821-d9k1zvqj
authors: Kim, Yeon-Sook; Aigerim, Abdimadiyeva; Park, Uni; Kim, Yuri; Park, Hyoree; Rhee, Ji-Young; Choi, Jae-Phil; Park, Wan Beom; Park, Sang Won; Kim, Yeonjae; Lim, Dong-Gyun; Choi, Ji-Yeob; Jeon, Yoon Kyung; Yang, Jeong-Sun; Lee, Joo-Yeon; Shin, Hyoung-Shik; Cho, Nam-Hyuk
title: Sustained responses of neutralizing antibodies against MERS-CoV in recovered patients and their therapeutic applicability
date: 2020-09-08
journal: Clin Infect Dis
DOI: 10.1093/cid/ciaa1345
sha: 20d89bf079453673cbdc60a4d36f21ef18c66339
doc_id: 703821
cord_uid: d9k1zvqj

BACKGROUND: Zoonotic coronaviruses have emerged as a global threat by causing fatal respiratory infections. Given the lack of specific antiviral therapies, application of human convalescent plasma retaining neutralizing activity could be a viable therapeutic option that can bridge this gap. METHODS: We traced antibody responses and memory B cells in peripheral blood collected from 70 recovered MERS-CoV patients for three years after the 2015 outbreak in South Korea. We also used a mouse infection model to examine whether the neutralizing activity of collected sera could provide therapeutic benefit in vivo upon lethal MERS-CoV challenge. RESULTS: Anti-spike-specific IgG responses, including neutralizing activity and antibody-secreting memory B cells, persisted for up to 3 years, especially in MERS patients that suffered from severe pneumonia. Mean antibody titers gradually decreased annually by less than two fold. Levels of antibody responses were significantly correlated with fever duration, viral shedding periods, and maximum viral loads observed during infection periods. In a transgenic mice model challenged with lethal doses of MERS-CoV, a significant reduction in viral loads and enhanced survival was observed when therapeutically treated with human plasma retaining high neutralizing titer (> 1/5,000). However, this failed to reduce pulmonary pathogenesis, as revealed by pathological changes in lungs and initial weight loss. CONCLUSIONS: High titers of neutralizing activity are required for suppressive effect on the viral replication but may not be sufficient to reduce inflammatory lesions upon fatal infection. Therefore, immune sera with high neutralizing activity must be carefully selected for plasma therapy of zoonotic coronavirus infection.

Zoonotic coronaviruses have been continuously emerging as global threats on public health by causing fatal respiratory diseases [1] . Severe acute respiratory syndrome coronavirus (SARS-CoV) arose in China and infected more than 8,000 victims, resulting in 774 deaths in 27 countries 2002 to 2003 [1] . Middle East respiratory syndrome coronavirus (MERS-CoV), originating from camels in the Middle East area, continues to cause outbreaks with high mortality (~ 35%) in 27 countries since 2012 [1, 2] . In December 2019, another novel coronavirus (SARS-CoV-2) emerged in Wuhan, China and has currently caused more than twenty million human infections with a global 3.6% mortality (https://covid19.who.int/). Despite the disastrous impact of the continuous emergence and spread of zoonotic coronaviruses on the human population, there is currently no specific antiviral therapy [3] . In addition, preventative vaccines against coronaviruses have not yet been approved for human application, although ongoing studies have demonstrated the potential of various candidate vaccines and monoclonal antibodies, especially those targeting viral spike antigens [4] .

Application of human sera or plasma collected from recovered patients that retain neutralizing activity has been clinically investigated for therapeutic use because of the ready availability of sera and plasma compared to other therapeutic options [5] [6] [7] . Although most of the studies were low quality, lacked control groups, and at moderate or high risk of bias, they consistently showed a reduction in mortality, especially when convalescent plasma is administered early after symptom onset [7] .

However, the minimum level of neutralizing activity of immune plasma for effective therapeutic application has been poorly defined [5, 6] . Therefore, evidence for this therapy would be strengthened by a well-designed clinical trial or other formal evaluation [7] [8] [9] .

Here, we traced antibody levels against spike antigen of MERS-CoV in recovered Korean patients who had confirmed MERS-CoV infection during the 2015 Korean outbreak. Spike specific antibody levels and neutralizing activity were extensively assessed by various techniques. In addition, we used a mouse infection model to examine whether the neutralizing activity of collected sera could provide therapeutic benefit in vivo upon lethal MERS-CoV challenge.

A c c e p t e d M a n u s c r i p t

We recruited 73 recovered MERS patients and their baseline characteristics are summarized in Table   1 . Sera and peripheral blood mononuclear cells (PBMCs) were collected from the participants at three-to-six-month intervals from 6 months after symptom onset. Sera from nine patients assessed in a previous study [10] were also included in this study. Clinical data and specimens obtained from the MERS patients were used in this study after ethnical approval granted by the institutional review 

The recovered patients were classified into three groups based on disease severity during the Korean MERS outbreak in 2015 [11] . Group I (G-I) includes 18 persons who were asymptomatic or had mild fever without developing pneumonia. Group II (G-II) includes 37 participants who developed mild pneumonia without hypoxemia. 18 people recovered after more prolonged and severe pneumonia and were classified as group III (G-III). G-III participants experienced hypoxemia and were treated with oxygen during hospitalization. Baseline characteristics of the severity groups are summarized in Table   1 .

First, we traced antibody responses against MERS-CoV spike antigen in 70 participants whose sera were available from 12 to 36 months after symptom onset (Figure 1a ). The average OD ratios against S1 spike antigen in all the samples were generally sustained for up to 36 months (mean ± S.D.: 1.56 ± 1.22, 1.90 ± 1.69, and 1.83 ± 1.55 at 12, 24, and 36 months, respectively) and were positively A c c e p t e d M a n u s c r i p t correlated with disease severity. In particular, the average antibody levels in patients of G-II (mean ± S.D.: 1.52 ± 1.06, 1.96 ± 1.58, and 1.92 ± 1.36 at 12, 24, and 36 months, respectively) and G-III (mean ± S.D.: 2.59 ± 1.16, 3.06 ± 1.70, and 2.74 ± 1.58 at 12, 24, and 36 months, respectively) did not significantly change, whereas those of G-I (mean ± S.D.: 0.56 ± 0.57, 0.48 ± 0.53, and 0.30 ± 0.34 at 12, 24, and 36 months, respectively) gradually declined. There were 50 patients whose sera were available at all the three year points and across all three groups. Only 1 person (9.1%, 1/11) in G-I We also measured antibody titers against spike antigen and neutralizing activity against spike pseudotyped lentivirus (ppNT 50 ) and MERS-CoV (PRNT 50 ) using sera from the 50 patients ( Figure   2 ). The antibody titers against spike antigen and the neutralizing titers against the pseudotyped lentivirus and MERS-CoV correlated well with OD ratio values against S1 antigen ( Figure 2 , left panels). In addition, the titers were generally higher in the patients that suffered from more severe MERS than those with milder symptoms as indicated by OD ratio values ( Figure 2 , right panels).

Antibody titers against spike antigen and the neutralizing titers generally declined, but by less than 2 fold every year. Average titers declined more rapidly in G-I and G-III groups, when compared to those of G-II. For example, average PRNT 50 titers of G-II patients were reduced by 20.5% at the third year (mean ± S.D.: 1,840 ± 2,350) when compared to those of the first year (2,322 ± 2,774), whereas those of G-I and G-III groups were reduced by 35.3% and 40.8%, respectively, at third year (G-I: 268

± 166, G-III: 2,220 ± 1,962) when compared to those of the first year (G-I: 415 ± 330, G-III: 3,751 ±

A c c e p t e d M a n u s c r i p t

In order to further confirm the spike-specific antibody responses, we measured spike-specific memory B cell responses on a cellular level by ELISPOT. PBMCs were taken at 12 and 36 months after infection from 36 subjects (G-I: n = 7, G-II: n = 16, and G-III: n = 13) and applied for analysis of spike antigen-specific IgG secreting memory B cells ( Figure 3 ). The number of spots in the 72 samples was overall positively correlated with OD ratio against S1 antigen (p = 0.0001). A positive correlation was observed in specimens from G-II subjects (p = 0.0150), whereas there were no significant correlations of the OD ratio with the spot counts in G-I and G-III samples (Figure 3b ). Finally, we evaluated the therapeutic efficacy of sera from the recovered patients. We selected three patients' sera with intermediate PRNT 50 titers (~ 1/1,000) and three additional sera with high PRNT 50 titers (> 1/5000) to generate pooled sera. A therapeutic human monoclonal antibody (3B11) [12, 13] against spike antigen was used as a positive control and pooled sera from healthy volunteers who never contacted MERS-CoV were used as a negative control. The antibody levels of each pooled sera were assessed by measuring OD ratio, anti-spike IgG titer, and PRNT 50 titer ( Table 2) [14] , in all the mice groups regardless of plasma therapy. Most of the infiltrating inflammatory cells were lymphocytes, monocytes/macrophages, plasma cells, and a few neutrophils. In addition, there was no significant difference in pulmonary pathology among the experimental groups, although the group treated with immune-sera with moderate neutralizing activity showed more variation in pathological grade (Figure 6a and b) . Moreover, there was no significant correlation between the degree of lung pathology and viral copies (Figure 6c IgG responses, including neutralizing antibodies, persisted for up to 3 years after the outbreak, especially in MERS patients that suffered from viral pneumonia, even though antibody titers gradually declined by less than two fold every year (Figure 1 and 2) . Similar trends of antibody kinetics have been reported in other longitudinal studies of smaller sample sizes within less than 3 years after initial MERS-CoV infection [10, 15, 16] . They showed that levels of specific antibody responses were significantly dependent on clinical severity and the duration of viral persistence [11, A c c e p t e d M a n u s c r i p t [16] [17] [18] [19] . We also found that levels of antibody response are significantly correlated with fever duration, viral shedding periods, and maximum viral loads (Figure 4 ). Of note, maximum viral loads in respiratory samples during the acute phase of infection showed the best correlation with antibody levels regardless of severity group in our study. These were further confirmed by the presence and persistence of memory B cells secreting specific antibodies (Figure 3 ). Since the specific antibody responses and memory B cells gradually decreased to undetectable levels in SARS patients at 6 years after infection [20] , the longevity and persistence of the MERS-specific humoral immunity needs to be determined in future studies.

Persistence of specific antibodies, neutralizing activity, and B cell memory in the recovered patients could be protective against reinfection [21] . Experimentally infected animals were protected or partially protected against reinfection of MERS-CoV [22] . However, evidence of natural reinfection of camels that were previously seropositive suggests that prior infection does not provide complete immunity from reinfection [23] . In addition, reinfection of MERS-CoV enhanced pulmonary inflammation in New Zealand white rabbits in the absence of neutralizing antibody [24] .

Nevertheless, there is some evidence that prior infection eliciting neutralizing activity or passive transfer of neutralizing antibody can protect animals from subsequent reinfection [24, 25] . Since there have been limited studies on reinfection in humans, careful monitoring of potential reinfection cases needs to be continued.

Passive antibody therapy using plasma from convalescent patients has been emergently applied in epidemics, such as the current COVID-19 pandemic, where there is insufficient time or resources to generate immunoglobulin therapy [26] . Indeed, several previous studies reported clinical benefits of plasma therapy by reducing viral loads and improving clinical symptoms in patients infected with emerging coronaviruses such as SARS-CoV-1, MERS-CoV, and SARS-CoV-2 [5, 8, [27] [28] [29] . Even though most of them have limitations such as small size samples, study design, and concomitant treatment modalities (i.e. simultaneous use of antiviral drugs and/or anti-inflammatory treatments), administration of convalescent plasma against the emerging CoVs is generally safe and provides clinical benefits, leading to calls for the wider adoption of plasma therapy for current viral pandemics [9, 26] . The antibodies present in immune sera can bind to a given pathogen, thereby directly A c c e p t e d M a n u s c r i p t neutralizing its infectivity, while other antibody-mediated effector functions including complement activation, antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP), may also contribute to its therapeutic effect [26] . Here, we observed significant reduction in viral loads and enhanced survival of a mouse model challenged with lethal MERS-CoV only when treated with plasma containing high titer (1/7,046) of neutralizing activity. However, this failed to reduce pulmonary pathogenesis upon lethal viral infection and plasma with moderate neutralizing titer (1/1,081) did not provide any clinical benefit. These results indicate that only high titers of neutralizing activity can provide suppressive effect on viral replication and subsequent spread, but is still not sufficient to reduce inflammatory lesions upon fatal MERS-CoV infection, as revealed by pathological changes in lungs and by initial weight loss regardless of plasma therapy.

Similar results were also reported in in vivo studies using common marmosets treated with hyperimmune plasma or monoclonal antibody against MERS-CoV [30] , and mouse model administered immune sera from camels [31] . Extra-neutralizing functions of antibodies, including complement-dependent cytotoxicity, ADCP, and ADCC, may have both protective and pathological consequences [32] . Antibody-dependent enhancement (ADE) of coronavirus entry into host cells has been continuously reported [33] [34] [35] , suggesting that ADE may occur under specific conditions in vivo, depending on antibody dose, binding affinity of the antibodies, and expression of viral and Fc receptors. In addition, a recent report showed that vaccine-induced antibodies may directly promote enhanced disease via macrophage-induced inflammatory chemokines and cytokines, resulting in lung injury during acute SARS-CoV infection [36] . Moreover, enhanced activation of complement [37] and/or elevated ADCC [38] , driven by antigen-antibody complexes, may also contribute to pulmonary pathogenesis during acute respiratory viral infection. Dissecting these properties of antibody response against emerging coronavirus infections is necessary for defining precise metrics of immunity, required for effective vaccines and therapeutics [32] . Therefore, feasibility, safety, and clinical effects of convalescent plasma therapy have to be properly assessed in ongoing clinical trials by determining appropriate neutralizing antibody titer, dose, or dosing range [39] . M a n u s c r i p t Table 2 .

Virus-challenged mice were monitored for 14 days to evaluate survival rate (left) and body weight changes (right). The body weight data are presented as means + SD of mice in each group (CNT: n = 5, moderate, high titer, and mAb/3B11: n = 8). Significant differences between the experimental group and control group (CNT) treated with non-immune sera are indicated (**, p < 0.01). b. MERS-CoV viral loads were assessed by measuring PFU (left) and copy numbers of viral RNA (right) in lung tissues collected at four days after infection. Statistical significance between the experiment group and control group was tested by using a two-tailed Student's t-test. *, p < 0.05; **, p < 0.01.

A c c e p t e d M a n u s c r i p t 

SARS and MERS: recent insights into emerging coronaviruses

Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission

Nucleoside analogues for the treatment of coronavirus infections

Antibodies and vaccines against Middle East respiratory syndrome coronavirus

Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia

Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience

The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

Convalescent Plasma to Treat COVID-19: Possibilities and Challenges

MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea

Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity

Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution

A mouse model for MERS coronavirus-induced acute respiratory distress syndrome

Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice

Persistence of Antibodies against Middle East Respiratory Syndrome Coronavirus

Antibody Response and Disease Severity in Healthcare Worker MERS Survivors

Kinetics of Serologic Responses to MERS Coronavirus Infection in Humans

Viral Shedding and Antibody Response in 37 Patients With Middle East Respiratory Syndrome Coronavirus Infection

Serologic responses of 42 MERS-coronavirus-infected patients according to the disease severity

Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study

Antibodies and B cell memory in viral immunity

Infection, Replication, and Transmission of Middle East Respiratory Syndrome Coronavirus in Alpacas

Longitudinal study of Middle East Respiratory Syndrome coronavirus infection in dromedary camel herds in Saudi Arabia

Enhanced inflammation in New Zealand white rabbits when MERS-CoV reinfection occurs in the absence of neutralizing antibody

Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice

Deployment of convalescent plasma for the prevention and treatment of COVID-19

Use of convalescent plasma therapy in SARS patients in Hong Kong

Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital

Convalescent plasma as a potential therapy for COVID-19

Efficacy of antibody-based therapies against Middle East respiratory syndrome coronavirus (MERS-CoV) in common marmosets

Passive immunotherapy with dromedary immune serum in an experimental animal model for Middle East respiratory syndrome coronavirus infection

Dissecting antibody-mediated protection against SARS-CoV-2

Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry

Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins

Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH-and cysteine protease-independent FcgammaR pathway

Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection

Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis

Antibody-Dependent Cell-Mediated Cytotoxicity Epitopes on the Hemagglutinin Head Region of Pandemic H1N1 Influenza Virus Play Detrimental Roles in H1N1-Infected Mice

Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol

A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t